Altimmune, Inc.
A clinical-stage biopharmaceutical company developing pemvidutide, a balanced GLP-1 and glucagon dual receptor agonist in late-stage trials for fatty-liver disease (MASH), alcohol use disorder, and alcohol-associated liver disease. It began in 1997 as vaccine maker Vaxin Inc. before renaming to Altimmune in 2015, and its early work included NasoVAX, a needle-free intranasal flu vaccine.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | 13G/APassive | 0.3% | 666.0K | May 15, 2026 |
| KEVIN TANG | 13G/APassive | 0.3% | 666.0K | May 15, 2026 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | 13G/APassive | 0.3% | 666.0K | May 15, 2026 |
| TANG CAPITAL PARTNERS, LP | 13G/APassive | 0% | 0 | May 15, 2026 |
| TANG CAPITAL PARTNERS III, INC | 13G/APassive | 0% | 0 | May 15, 2026 |
| TANG CAPITAL PARTNERS IV, INC | 13G/APassive | 0% | 0 | May 15, 2026 |
| STATE STREET CORPORATION | 13GPassive | 5.5% | 7.15M | May 12, 2026 |
| Chen Yu | 13GPassive | 9.8% | 20.00M | May 1, 2026 |
| VIKING GLOBAL INVESTORS LP | 13GPassive | 6.7% | 13.40M | May 1, 2026 |
| Viking Global Opportunities Parent GP LLC | 13GPassive | 6.7% | 13.40M | May 1, 2026 |